| Primary |
| Hiv Infection |
71.9% |
| Antiretroviral Therapy |
15.5% |
| Acquired Immunodeficiency Syndrome |
1.8% |
| Retroviral Infection |
1.5% |
| Tuberculosis |
1.4% |
| Hiv Test Positive |
1.1% |
| Systemic Antiviral Treatment |
1.1% |
| Hepatitis C Virus Test |
0.8% |
| Drug Use For Unknown Indication |
0.7% |
| Drug Exposure During Pregnancy |
0.6% |
| Hepatitis C |
0.5% |
| Prophylaxis |
0.5% |
| Hypertension |
0.4% |
| Urticaria |
0.4% |
| Acne |
0.4% |
| Alcohol Abuse |
0.4% |
| Back Pain |
0.3% |
| Depression |
0.3% |
| Human Immunodeficiency Virus Transmission |
0.3% |
| Infection |
0.3% |
|
| Portal Hypertension |
13.1% |
| Pancreatitis |
10.2% |
| Nodular Regenerative Hyperplasia |
9.1% |
| Pregnancy |
8.0% |
| Varices Oesophageal |
8.0% |
| Nephropathy Toxic |
5.7% |
| Encephalopathy |
5.1% |
| Vomiting |
4.5% |
| Drug Exposure During Pregnancy |
4.0% |
| Hepatic Cirrhosis |
4.0% |
| Portal Vein Thrombosis |
4.0% |
| Sepsis |
4.0% |
| Weight Decreased |
3.4% |
| Splenomegaly |
2.8% |
| Ventricular Septal Defect |
2.8% |
| Death |
2.3% |
| Drug Resistance |
2.3% |
| Hypokalaemia |
2.3% |
| Renal Failure |
2.3% |
| Retinal Toxicity |
2.3% |
|
| Secondary |
| Hiv Infection |
68.8% |
| Antiretroviral Therapy |
6.5% |
| Drug Use For Unknown Indication |
5.4% |
| Drug Exposure During Pregnancy |
3.5% |
| Acquired Immunodeficiency Syndrome |
1.7% |
| Human Immunodeficiency Virus Transmission |
1.7% |
| Product Used For Unknown Indication |
1.7% |
| Prophylaxis |
1.5% |
| Hepatitis C |
1.4% |
| Retroviral Infection |
1.0% |
| Prophylaxis Against Transplant Rejection |
0.9% |
| Insomnia |
0.8% |
| Antiviral Prophylaxis |
0.8% |
| Hypertension |
0.7% |
| Systemic Antiviral Treatment |
0.7% |
| Hiv Test Positive |
0.7% |
| Prophylaxis Against Hiv Infection |
0.6% |
| Factor Viii Deficiency |
0.5% |
| Pneumocystis Jiroveci Infection |
0.5% |
| Gastritis |
0.5% |
|
| Progressive External Ophthalmoplegia |
10.4% |
| Portal Hypertension |
7.6% |
| Varices Oesophageal |
7.6% |
| Vomiting |
6.6% |
| Osteonecrosis |
6.4% |
| Umbilical Cord Abnormality |
5.8% |
| Weight Decreased |
5.4% |
| Drug Resistance |
4.8% |
| Stillbirth |
4.6% |
| Pancreatitis |
4.4% |
| Premature Baby |
4.4% |
| Abortion Spontaneous |
4.2% |
| Urine Colour Abnormal |
3.8% |
| Pregnancy |
3.6% |
| Transplant Rejection |
3.6% |
| Drug Exposure During Pregnancy |
3.4% |
| White Blood Cell Count Decreased |
3.4% |
| Pneumonia |
3.2% |
| Splenomegaly |
3.2% |
| Virologic Failure |
3.2% |
|
| Concomitant |
| Hiv Infection |
61.7% |
| Drug Use For Unknown Indication |
16.3% |
| Product Used For Unknown Indication |
3.8% |
| Acquired Immunodeficiency Syndrome |
3.8% |
| Antibiotic Prophylaxis |
1.6% |
| Prophylaxis |
1.5% |
| Antiretroviral Therapy |
1.3% |
| Antifungal Prophylaxis |
1.0% |
| Medical Diet |
1.0% |
| Hypertension |
1.0% |
| Depression |
0.9% |
| Tuberculosis |
0.9% |
| Chronic Obstructive Pulmonary Disease |
0.8% |
| Infection Prophylaxis |
0.7% |
| Neuropathy Peripheral |
0.7% |
| Drug Hypersensitivity |
0.7% |
| Prostate Cancer |
0.7% |
| Diarrhoea |
0.6% |
| Pain |
0.6% |
| Hepatitis C |
0.6% |
|
| Weight Decreased |
16.3% |
| Death |
9.2% |
| Vomiting |
7.6% |
| Suicidal Ideation |
5.6% |
| Coronary Artery Disease |
5.2% |
| Osteomalacia |
5.2% |
| Renal Failure |
4.8% |
| Osteonecrosis |
4.4% |
| Renal Failure Acute |
4.4% |
| Rhabdomyolysis |
4.4% |
| Viral Load Increased |
4.4% |
| Upper Gastrointestinal Haemorrhage |
3.6% |
| Urticaria |
3.6% |
| Abortion Spontaneous |
3.2% |
| Drug Interaction |
3.2% |
| Renal Impairment |
3.2% |
| Sepsis |
3.2% |
| Weight Increased |
3.2% |
| Drug Exposure During Pregnancy |
2.8% |
| Renal Tubular Necrosis |
2.8% |
|
| Interacting |
| Hiv Infection |
61.2% |
| Antiretroviral Therapy |
9.0% |
| Drug Use For Unknown Indication |
7.5% |
| Lung Neoplasm Malignant |
4.5% |
| Fungal Infection |
2.2% |
| Neuropathy Peripheral |
2.2% |
| Prophylaxis |
2.2% |
| Alcohol Abuse |
1.5% |
| Convulsion |
1.5% |
| Cytomegalovirus Enteritis |
1.5% |
| Hypertensive Heart Disease |
1.5% |
| Hypertensive Nephropathy |
1.5% |
| Hepatic Neoplasm Malignant |
0.7% |
| Hypertension |
0.7% |
| Insomnia |
0.7% |
| Product Used For Unknown Indication |
0.7% |
| Pulmonary Embolism |
0.7% |
|
| Drug Interaction |
18.2% |
| Nephrogenic Diabetes Insipidus |
13.6% |
| Thrombocytopenia |
9.1% |
| Abdominal Pain |
4.5% |
| Blood Ph Decreased |
4.5% |
| Embolism Venous |
4.5% |
| Multi-organ Failure |
4.5% |
| Pancreatitis |
4.5% |
| Pancreatitis Acute |
4.5% |
| Pancytopenia |
4.5% |
| Renal Failure Acute |
4.5% |
| Renal Tubular Disorder |
4.5% |
| Retinal Toxicity |
4.5% |
| Transaminases Increased |
4.5% |
| Viral Load Increased |
4.5% |
| Weight Increased |
4.5% |
|
